More than 300 million people worldwide live with a rare disease. Yet despite remarkable scientific advances, many patients continue to face delayed diagnoses, limited treatment options, and unequal access to innovative therapies.
Today, however, the conversation around rare diseases is evolving.
The focus is no longer solely on developing new treatments. Increasingly, attention is shifting towards how healthcare systems evaluate, fund, and provide access to innovations designed for small patient populations, particularly as advanced therapies and gene therapies continue to reshape the treatment landscape.
Recent developments across Europe highlight the growing relevance of this discussion. The implementation of the European HTA Regulation through Joint Clinical Assessments, together with ongoing reforms to pricing and reimbursement frameworks in countries such as Spain, reflects a broader transformation in healthcare decision-making. Healthcare systems are seeking a balance between consistency in assessment, sustainability of resources, equitable access, and timely patient access to innovation.
Rare diseases challenge many of the assumptions on which traditional assessment frameworks were built:
These challenges do not eliminate the need for decisions. On the contrary, they make robust and meaningful decision-making even more critical.
In this context, Health Economics and Outcomes Research becomes increasingly relevant, not because it removes uncertainty, but because it helps place available evidence into a broader perspective. Understanding disease burden, patient-reported outcomes, caregiver impact, real-world outcomes, and long-term societal benefits is essential to capturing the full value of healthcare interventions.
Rare diseases are forcing healthcare systems to move beyond a narrow definition of value.
For many innovative therapies, particularly in areas of high unmet need, value cannot be fully understood through traditional clinical endpoints or short-term budget considerations alone. The impact on patients' daily lives, caregiver burden, long-term health outcomes, and participation in society are becoming increasingly important components of the discussion.
As healthcare systems across Europe continue to refine how therapies are assessed and funded, rare diseases may become one of the most important testing grounds for the future of healthcare decision-making.
The challenge is not simply generating more evidence. It is ensuring that the evidence we generate reflects what truly matters.
In many ways, rare diseases are no longer adapting to existing value frameworks. They are redefining how value itself is understood.
If limited evidence is an inherent reality in rare diseases, how should healthcare systems adapt their decision-making frameworks to ensure patients are not left behind?
Authors:
Lorena Esteban, Value Evidence & Medical Strategy, Senior Consultant – Outcomes'10 a PLG Company